Plasticity of the Mycobacterium tuberculosis respiratory chain and its impact on tuberculosis drug development

@article{Beites2019PlasticityOT,
  title={Plasticity of the Mycobacterium tuberculosis respiratory chain and its impact on tuberculosis drug development},
  author={Tiago Beites and K. O'Brien and D. Tiwari and Curtis A. Engelhart and Shaun B Walters and Jenna Andrews and Hee-Jeong Yang and Michelle L. Sutphen and Danielle M. Weiner and E. Dayao and M. Zimmerman and Brendan Prideaux and P. Desai and T. Masquelin and L. Via and V. Dartois and H. Boshoff and C. Barry and S. Ehrt and D. Schnappinger},
  journal={Nature Communications},
  year={2019},
  volume={10}
}
The viability of Mycobacterium tuberculosis (Mtb) depends on energy generated by its respiratory chain. Cytochrome bc1-aa3 oxidase and type-2 NADH dehydrogenase (NDH-2) are respiratory chain components predicted to be essential, and are currently targeted for drug development. Here we demonstrate that an Mtb cytochrome bc1-aa3 oxidase deletion mutant is viable and only partially attenuated in mice. Moreover, treatment of Mtb-infected marmosets with a cytochrome bc1-aa3 oxidase inhibitor… Expand
Host immunity increases Mycobacterium tuberculosis reliance on cytochrome bd oxidase
TLDR
A critical interaction between host immunity and pathogen respiration that influences both the progression of the infection and the efficacy of potential new TB drugs is identified. Expand
Host immunity increases Mycobacterium tuberculosis reliance on cytochrome bd oxidase
TLDR
A critical interaction between host immunity and pathogen respiration that influences both the progression of the infection and the efficacy of potential new TB drugs is identified. Expand
Targeting the cytochrome oxidases for drug development in mycobacteria.
TLDR
Current knowledge about the two mycobacterial aerobic respiratory branches, their potential as drug targets, as well as potential drawbacks are discussed. Expand
Impaired succinate oxidation prevents growth and influences drug susceptibility in Mycobacterium tuberculosis
TLDR
It is demonstrated that impaired succinate oxidation prevents the optimal growth of M. tuberculosis on a range of carbon sources and significantly reduces the activity of the electron transport chain and both positively and negatively influences theActivity of a variety of anti-tuberculosis drugs. Expand
Dual inhibition of the terminal oxidases eradicates antibiotic‐tolerant Mycobacterium tuberculosis
TLDR
It is suggested that a cytochrome bd oxidase inhibitor will add value to a drug combination targeting oxidative phosphorylation for tuberculosis treatment. Expand
SAR Analysis of Small Molecules Interfering with Energy-Metabolism in Mycobacterium tuberculosis
TLDR
This review describes potent anti-mycobacterial agents targeting the energy-metabolism at different steps with a special focus on structure-activity relationship (SAR) studies of the most advanced compound classes. Expand
Terminal Respiratory Oxidases: A Targetables Vulnerability of Mycobacterial Bioenergetics?
TLDR
The current understanding of the functioning of these two oxidases, their physiological relevance to mycobacteria, and their inhibitors are described are described, and the alternative terminal complexes that are used by myCobacteria to maintain energized membrane during hypoxia and anaerobic conditions are described. Expand
Nitric oxide-inducible Fe-S cluster biogenesis enables Mycobacterium tuberculosis to persist in mice
TLDR
It is shown that Mtb utilizes the suf operon for Fe-S cluster biogenesis to persist under NO stress and data suggest that SufR is a sensor of NO that supports persistence by reprogramming Fe- S cluster metabolism and bioenergetics of Mtb. Expand
Mycobacterium tuberculosis SufR Responds to Nitric oxide via its 4Fe-4S cluster and Regulates Fe-S cluster Biogenesis for Persistence in Mice
TLDR
SufR is a sensor of NO that supports persistence by reprogramming Fe-S cluster metabolism and bioenergetics and confers respiratory and redox features that promote recovery of Mtb from NO stress. Expand
Screening of Compounds for Anti-tuberculosis Activity, and in vitro and in vivo Evaluation of Potential Candidates
  • Wei Zhou, Bing Yang, +7 authors G. Cao
  • Medicine
  • Frontiers in Microbiology
  • 2021
TLDR
The potential ability of orbifloxacin as an anti-tuberculosis drug, which can be used either alone or in combination with first-line antibiotics to achieve more effective therapy on TB is indicated. Expand
...
1
2
3
...

References

SHOWING 1-10 OF 55 REFERENCES
Plasticity of Mycobacterium tuberculosis NADH dehydrogenases and their role in virulence
TLDR
Ndh is the main NADH dehydrogenase of Mtb and that compounds that could target both Ndh and Nuo would be good candidates for TB drug development, suggesting a key role for Nuo in vivo when Ndh is absent. Expand
Small Molecules Targeting Mycobacterium tuberculosis Type II NADH Dehydrogenase Exhibit Antimycobacterial Activity.
TLDR
The identification of two types of small molecules as selective inhibitors for Ndh-2 through a multicomponent high-throughput screen and these two scaffolds have differential inhibitory activities against the two homologous Ndh -2 enzymes in Mtb, which will allow precise control over N dh-2 function in MtB to facilitate the assessment of this anti-TB drug target. Expand
Exploiting the synthetic lethality between terminal respiratory oxidases to kill Mycobacterium tuberculosis and clear host infection
TLDR
It is shown that the electron flow through the cytochrome bd oxidase is sufficient to maintain respiration and ATP synthesis at a level high enough to protect M. tuberculosis from Q203-induced bacterial death. Expand
Turning the respiratory flexibility of Mycobacterium tuberculosis against itself
TLDR
It is found that Mtb's ETC rapidly reroutes around inhibition by these drugs and increases total respiration to maintain ATP levels, indicating that combination therapy targeting the ETC can be exploited to enhance killing of Mtb. Expand
Inhibitors of type II NADH:menaquinone oxidoreductase represent a class of antitubercular drugs.
  • E. Weinstein, T. Yano, +7 authors H. Rubin
  • Biology, Medicine
  • Proceedings of the National Academy of Sciences of the United States of America
  • 2005
TLDR
A detailed biochemical characterization of the aerobic respiratory chains from Mtb is presented and it is shown that phenothiazine analogs specifically inhibit NADH:menaquinone oxidoreductase activity. Expand
Pyrazolo[1,5- a]pyridine Inhibitor of the Respiratory Cytochrome bcc Complex for the Treatment of Drug-Resistant Tuberculosis.
TLDR
It is proposed that TB47 is an effective lead compound for the development of novel tuberculosis chemotherapies, suggesting a promising role in combination therapies. Expand
Changes in energy metabolism of Mycobacterium tuberculosis in mouse lung and under in vitro conditions affecting aerobic respiration
TLDR
Investigation of genes encoding components of the respiratory chain and the ATP synthesizing apparatus of Mycobacterium tuberculosis in mice infected with a cydC mutant at the transition to chronic infection provided initial evidence that the bd oxidase pathway is required for M. tuberculosis adaptation to host immunity. Expand
Enhanced respiration prevents drug tolerance and drug resistance in Mycobacterium tuberculosis
TLDR
It is discovered that the combination of cysteine or other small thiols with either isoniazid or rifampicin prevents the formation of drug-tolerant and drug-resistant cells in Mtb cultures, leading to mycobacterial cell death. Expand
Transcriptional Adaptation of Mycobacterium tuberculosis within Macrophages
TLDR
The microbial transcriptome served as a bioprobe of the MTB phagosomal environment, showing it to be nitrosative, oxidative, functionally hypoxic, carbohydrate poor, and capable of perturbing the pathogen's cell envelope. Expand
Activation of type II NADH dehydrogenase by quinolinequinones mediates antitubercular cell death.
TLDR
Q8c targets NDH-2 of the mycobacterial respiratory chain leading to activation of NADH oxidation and generating bactericidal levels of ROS in a manner similar to, but more effectively than, the antimycob bacterial drug clofazimine. Expand
...
1
2
3
4
5
...